[1] ZHAO R H, SHI Y, ZHAO H, et al. Acute-on-chronic liver failure in chronic hepatitis B: an update [J]. Expert review of gastroenterology & hepatology, 2018, 12(4): 341-50.
[2] SARIN S K, CHOUDHURY A, SHARMA M K, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update [J]. Hepatol Int, 2019,
[3] EUROPEAN ASSOC STUDY L. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure [J]. Journal of hepatology, 2017, 66(5): 1047-81.
[4] SUN L J, YU J W, ZHAO Y H, et al. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure [J]. Journal of gastroenterology and hepatology, 2010, 25(3): 583-90.
[5] OHATA K, HAMASAKI K, TORIYAMA K, et al. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection [J]. Journal of gastroenterology and hepatology, 2004, 19(6): 670-5.
[6] CHOI G H, KIM G-A, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation [J]. Alimentary pharmacology & therapeutics, 2019, 50(2): 215-26.
[7] TERRAULT N A, LOK A S F, MCMAHON B J, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance [J]. Hepatology (Baltimore, Md), 2018, 67(4): 1560-99.
[8] AGARWAL K, BERG T, BUTI M, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection European Association for the Study of the Liver [J]. Journal of hepatology, 2017, 67(2): 370-98.
[9] TERRAULT N A, BZOWEJ N H, CHANG K-M, et al. AASLD guidelines for treatment of chronic hepatitis B [J]. Hepatology (Baltimore, Md), 2016, 63(1): 261-83.
[10] CUI Y-L, YAN F, WANG Y-B, et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure [J]. Digestive diseases and sciences, 2010, 55(8): 2373-80.
[11] CHEN J, HAN J-H, LIU C, et al. Short-term entecavir therapy of chronic severe hepatitis B [J]. Hepatobiliary & pancreatic diseases international : HBPD INT, 2009, 8(3): 261-6.
[12] MA K, GUO W, HAN M, et al. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model [J]. Hepatol Int, 2012, 6(4): 735-43.
[13] LIN B, PAN C Q, XIE D, et al. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B [J]. Hepatol Int, 2013, 7(2): 460-7.
[14] LAI J, YAN Y, MAI L, et al. Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure [J]. Hepatobiliary & pancreatic diseases international : HBPD INT, 2013, 12(2): 154-9.
[15] LI X, GAO F, LIU H, et al. Lamivudine improves short-term outcome in hepatitis B virus-related acute-on-chronic liver failure patients with a high model for end-stage liver disease score [J]. European journal of gastroenterology & hepatology, 2017, 29(1): 1-9.
[16] WONG V W, WONG G L, YIU K K, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B [J]. Journal of hepatology, 2011, 54(2): 236-42.
[17] LANGE C M, BOJUNGA J, HOFMANN W P, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function [J]. Hepatology (Baltimore, Md), 2009, 50(6): 2001-6.
[18] GARG H, SARIN S K, KUMAR M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure [J]. Hepatology (Baltimore, Md), 2011, 53(3): 774-80.
[19] WAN Y M, LI Y H, XU Z Y, et al. Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C [J]. Journal of clinical gastroenterology, 2018,
[20] MURAKAMI E, WANG T, PARK Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy [J]. Antimicrobial agents and chemotherapy, 2015, 59(6): 3563-9.
[21] BUTI M, GANE E, SETO W K, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial [J]. The lancet Gastroenterology & hepatology, 2016, 1(3): 196-206.
[22] CHAN H L Y, FUNG S, SETO W K, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial [J]. The lancet Gastroenterology & hepatology, 2016, 1(3): 185-95.
[23] KAMATH P S, KIM W R. The model for end-stage liver disease (MELD) [J]. Hepatology (Baltimore, Md), 2007, 45(3): 797-805.
[24] KAMATH P S, WIESNER R H, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease [J]. Hepatology (Baltimore, Md), 2001, 33(2): 464-70.
[25] FRANCOZ C, DURAND F, KAHN J A, et al. Hepatorenal Syndrome [J]. Clin J Am Soc Nephrol, 2019, 14(5): 774-81.
[26] CHEN T, HE Y, LIU X, et al. Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure [J]. Clinical and experimental medicine, 2012, 12(3): 159-64.
[27] TSAI W L, CHIANG P H, CHAN H H, et al. Early entecavir treatment for chronic hepatitis B with severe acute exacerbation [J]. Antimicrobial agents and chemotherapy, 2014, 58(4): 1918-21.
[28] YANG J, SUN H, LIU Q. The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis [J]. Gastroenterology research and practice, 2016, 2016(5802674.
[29] ZHANG Y, HU X Y, ZHONG S, et al. Entecavir vs lamivudine therapy for naive patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure [J]. World J Gastroenterol, 2014, 20(16): 4745-52.
[30] ZHANG X, AN Y, JIANG X, et al. Entecavir versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure: a meta-analysis [J]. Hepat Mon, 2014, 14(11): e19164.
[31] CHEN C-H, LIN C-L, HU T-H, et al. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation [J]. Journal of hepatology, 2014, 60(6): 1127-34.
[32] HUNG C H, HU T H, LU S N, et al. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation [J]. Antimicrobial agents and chemotherapy, 2015, 59(6): 3168-73.
[33] ABDUL BASIT S, DAWOOD A, RYAN J, et al. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection [J]. Expert review of clinical pharmacology, 2017, 10(7): 707-16.
[34] AGARWAL K, BRUNETTO M, SETO W K, et al. 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection [J]. Journal of hepatology, 2018, 68(4): 672-81.
[35] SCHWARZE‐ZANDER C, PIDUHN H, BOESECKE C, et al. Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications? [J]. HIV medicine, 2020,
[36] LAMPERTICO P, BUTI M, FUNG S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study [J]. The lancet Gastroenterology & hepatology, 2020,
[37] CICOGNANI C, MALAVOLTI M, MORSELLI-LABATE A M, et al. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis [J]. Arch Intern Med, 1997, 157(7): 792-6.
[38] TRIEB M, RAINER F, STADLBAUER V, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure [J]. Journal of hepatology, 2020,